Annals of Cancer Research and Therapy
Online ISSN : 1880-5469
Print ISSN : 1344-6835
ISSN-L : 1344-6835
Fecal Calprotectin: A Predictive Biomarker for Gastrointestinal Graft-versus-Host-Disease and a Prognostic Indicator in their Steroid therapy
Elham RoshandelSayeh ParkhidehMozhdeh MohammadianSedigheh sadat AkhlaghiShayan ZamaniMohammad Reza MoshariMahmoud Dehghani Ghorbi
著者情報
ジャーナル フリー

2024 年 32 巻 2 号 p. 39-44

詳細
抄録

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a promising therapeutic approach with risk of Acute Graft-versus-Host-Disease (aGvHD). aGvHD can affect the gastrointestinal tract, which results in gastrointestinal-GvHD (GI-GvHD). We assessed fecal calprotectin (FC) to determine if it can be applied as a GI-GvHD diagnostic marker and the response to steroid therapy.

Methods: We measured FC levels in patients who received allo-HSCT from full-matched donors using ELISA. Sample collection was performed prior to HSCT, at the GvHD onset of symptoms, and at intervals of seven days and three weeks following initiating steroid therapy.

Results: A total of 25 patients were evaluated. The FC values were significantly higher in GvHD patients than in the control group. The difference between FC values in patients with various stages of GvHD was not statistically significant. The cut-off level of FC for anticipating GI-GvHD onset was 103.5 μg/g with a sensitivity of 46% and specificity of 91.5%. The mean of FC values was significantly higher in steroid-resistant patients than in steroid responder patients.

Conclusion: Our findings indicated that FC could be utilized in GI-GvHD diagnosis and predicting its happening risk. FC has high potency in predicting the response to steroid therapy.

著者関連情報
© 2024 by The Japanese Society of Strategies for Cancer Research and Therapy
前の記事 次の記事
feedback
Top